Insights & Resources | Pfizer CentreOne

Balancing Pressing Priorities

In the latest roundtable discussion with BioPharm International, our contract manufacturing lead Tom Wilson spoke alongside other industry leaders about these supply chain challenges and how we were able to change our business processes and develop best practices to ensure effective remote partnerships.

Considerations for Migrating a Drug Product Presentation from Vial to Pre-Filled Syringe

This whitepaper outlines the benefits of PFS transfer, the differences between glass and PFS devices, and the key engineering processes required to successfully carry out this process.

Exploring best-practice manufacturing strategies for highly potent oral solid dosage forms

In this white paper Pfizer CentreOne examines what developers and their manufacturing partners need to know about its unique regulatory challenges and how to navigate HPOSD’s complex manufacturing environment successfully.

Placing Drug Strategies on a Solid Foundation for Success

Our whitepaper explores current market dynamics and the latest drug development trends driving these strategic outsourcing decisions.

Migrating A Drug Product Presentation From Vial To Prefilled Syringe - On Drug Delivery

This article explores some of the leading engineering activities that are necessary for successful PFS transfers and the benefits they offer.

Understanding the Challenges of Highly Potent Actives - International Pharmaceutical Industry

From managing health and safety risks to effective potency classifications, there are many challenges pharmaceutical companies face when using highly potent active pharmaceutical ingredients (HPAPIs) for the first time. This article explores these challenges in-depth and how they can be overcome.

Pfizer CenterOne’s Enviero® receives first EU authorization as part of ESTIMA® (progesterone) product approval.

Pfizer CentreOne’s green-chemistry progesterone API, Enviero®, has been approved for use in the EU for the first time in a drug product manufactured by French pharmaceutical company, Effik.

Highly Potent Oral Solids: Top Considerations

Understanding product classification and the heightened complexity of HPAPI drug substance transfer and manufacturing is critical. Developers are increasingly working with CDMOs to commercialize their HPAPIs. Kieran Coffey, Technical Services Lead at Pfizer CentreOne, discusses these key considerations

Experience the Art of Science - Debbie Lemons's story

In this instalment of our ‘Experience the Art of Science’ blog series, we meet Debbie Lemons, Senior Regulatory Compliance External Lead Auditor at our Rocky Mount facility.

Building More Resilient API Supply Chains

Safe, secure and reliable supply lines for key medicines is one of pharma's top priorities. However, as recent reports about shortages of active pharmaceutical ingredients (APIs) impacting on the supply of key medicines show, there are lessons to be learned to ensure optimum supply chain security.

How to Secure a Sustainable Supply of Raw Materials

There are a few steps pharmaceutical companies can take to minimize insecurity in their supply chain even in a rapidly changing market, find out what these are in this article.

Your Questions Answered - Highly Potent Oral Solids Q&A

Pfizer CentreOne’s OSD experts answer your questions following our recent webinar on the challenges and considerations for a highly potent oral solids project.